Mitochondrial biotech Minovia Therapeutics nabs biopharma veteran Alan Jacobs as new chief medical officer
(Getty/FamVeld) As it awaits FDA feedback on its pivotal trial for its leading med, Minovia Therapeutics has hired Alan Jacobs, M.D., Ph.D., to help boost it over the line. The U.S.-Israel biotech, which uses a platform to augment disease caused by mitochondrial dysfunction, will now tap Jacobs’ 20 years’ experience at companies including Aspire Health Science, Hemostemix and PerceptiMed. As CMO, he will now lead Minovia’s clinical operations and regulatory affairs, including speeding up the development plans for Pearson Syndrome and other “primary and secondary mitochondria...